The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Antibody and T-cell responses to COVID-19 vaccination in patients with MPNs
In this video, Gabriela Hobbs, MD, Massachusetts General Hospital, Boston, MA, highlights some findings from a study which aimed to investigate the response of myeloproliferative neoplasm (MPN) patients to COVID-19 vaccination. Dr Hobbs first explains how patient samples were collected, and then discusses some of the positive results that were obtained, comparing both serologic and T-cell responses to vaccination in different patient cohorts. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
